Dyne Therapeutics (NASDAQ:DYN) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock.

DYN has been the topic of a number of other reports. Piper Sandler boosted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Raymond James increased their target price on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the stock a strong-buy rating in a report on Thursday, January 4th. Oppenheimer reissued an outperform rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, March 26th. Chardan Capital upped their price objective on Dyne Therapeutics from $20.00 to $31.00 and gave the stock a buy rating in a research report on Friday, March 8th. Finally, Morgan Stanley started coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an overweight rating and a $40.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $37.75.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $26.25 on Friday. Dyne Therapeutics has a fifty-two week low of $6.40 and a fifty-two week high of $30.27. The company has a 50 day moving average price of $26.45 and a 200 day moving average price of $18.70. The stock has a market capitalization of $2.29 billion, a P/E ratio of -6.61 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.17). Research analysts forecast that Dyne Therapeutics will post -3.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the completion of the sale, the insider now directly owns 6,631,464 shares of the company’s stock, valued at approximately $149,672,142.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Susanna Gatti High sold 2,292 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $58,904.40. Following the transaction, the chief operating officer now directly owns 156,800 shares of the company’s stock, valued at approximately $4,029,760. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the completion of the sale, the insider now directly owns 6,631,464 shares of the company’s stock, valued at $149,672,142.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,875,432 shares of company stock worth $44,368,530. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. Fcpm Iii Services B.V. acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $81,543,000. Braidwell LP grew its position in shares of Dyne Therapeutics by 32.2% during the third quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after acquiring an additional 444,100 shares during the last quarter. Vivo Capital LLC increased its holdings in shares of Dyne Therapeutics by 58.0% in the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock valued at $46,422,000 after acquiring an additional 600,000 shares during the period. Jennison Associates LLC raised its position in Dyne Therapeutics by 495.2% in the 1st quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after purchasing an additional 1,004,680 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in Dyne Therapeutics by 31.6% during the 3rd quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock worth $10,752,000 after purchasing an additional 288,000 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.